```html

Kollagenous Colitis – A Comprehensive Medical Guide

Overview

Kollagenous colitis (also spelled “collagenous colitis”) is a form of microscopic colitis, a group of inflammatory bowel disorders that cause chronic watery diarrhea. Unlike ulcerative colitis or Crohn’s disease, the colon looks normal during a routine endoscopy; the inflammation is only visible under a microscope. The defining feature of kollagenous colitis is a thickened subepithelial collagen band (≥10 µm) beneath the surface lining of the colon.

Who it affects: It predominantly affects adults over the age of 50, with a strong female predominance (approximately 70‑80 % of cases are women). However, younger adults and men can also be diagnosed.

Prevalence: Microscopic colitis (including both collagenous and lymphocytic subtypes) is estimated to affect 100–200 per 100,000 persons in the United States and Europe. Collagenous colitis accounts for roughly 30‑40 % of these cases, translating to about 30–80 cases per 100,000 people <sup>1</sup>. Incidence appears to be rising, likely due to increased awareness and more frequent colonoscopic biopsies.

Symptoms

Symptoms are usually insidious, developing over weeks to months. The most common complaints are:

• Watery, non‑bloody diarrhea: Often ≥3 loose stools per day; urgency may be pronounced.
• Nocturnal diarrhea: Stools that occur while sleeping, disrupting sleep.
• Abdominal cramping or pain: Usually mild to moderate, often described as a “tenesmus‑like” sensation.
• Fatigue: Resulting from dehydration, electrolyte loss, or disrupted sleep.
• Weight loss: Usually modest (<10 % of body weight) but can occur if diarrhea is severe.
• Fecal urgency and incontinence: Due to rapid transit.
• Flatulence and bloating: Gas accumulation from altered motility.

Less common manifestations include:

• Fever – typically absent; when present, consider infection.
• Blood or mucus in stool – rare; if noted, evaluate for other colitis types.
• Joint or muscle aches – occasional extra‑intestinal complaints.

Causes and Risk Factors

The exact cause of kollagenous colitis remains unclear, but several mechanisms have been proposed:

Immune‑mediated inflammation

Auto‑reactive T‑cell activity may trigger cytokine release, leading to fibroblast activation and collagen deposition in the colonic lamina propria.

Medication‑related triggers

Up to 40 % of patients report recent or chronic use of certain drugs, including:

• Non‑steroidal anti‑inflammatory drugs (NSAIDs) – ibuprofen, naproxen.
• Selective serotonin reuptake inhibitors (SSRIs) – sertraline, fluoxetine.
• Proton pump inhibitors (PPIs) – omeprazole, pantoprazole.
• Beta‑blockers, statins, and antihypertensives.

Infections

Post‑infectious colitis after bacterial gastroenteritis (e.g., Campylobacter, Salmonella) has been described, suggesting a “second‑hit” phenomenon.

Autoimmune overlap

Patients often have other autoimmune conditions such as celiac disease, thyroiditis, or rheumatoid arthritis, supporting an immune dysregulation hypothesis.

Risk factors

• Age > 50 years.
• Female sex.
• Chronic use of NSAIDs, PPIs, or SSRIs.
• History of autoimmune disease.
• Smoking – modest association.

Diagnosis

Because the colon appears normal during endoscopy, diagnosis relies on a combination of clinical suspicion and histopathologic examination.

Step‑by‑step diagnostic pathway

1. Clinical assessment: Detailed history of stool pattern, medication use, and associated systemic symptoms.
2. Laboratory tests: CBC, electrolytes, C‑reactive protein (CRP), and stool studies to rule out infection (cultures, Clostridioides difficile PCR).
3. Colonoscopy with targeted biopsies: Multiple (≥6) random biopsies from the right colon, transverse colon, and rectosigmoid area. The collagen band thickness is measured under light microscopy.
4. Histopathology: Diagnostic criteria include:
   • Subepithelial collagen band ≥10 µm.
   • Surface epithelial injury (epithelial sloughing, crypt distortion).
   • Intra‑epithelial lymphocytosis (often <30 cells/100 epithelial cells, less than in lymphocytic colitis).

Additional tests may be ordered to assess for associated conditions:

• Serology for tissue transglutaminase IgA (celiac disease).
• Thyroid function tests.
• Autoimmune panels if clinically indicated.

Treatment Options

Treatment aims to control diarrhea, restore quality of life, and address any underlying contributors.

Medication‑based therapies

• Budesonide (topical glucocorticoid): First‑line agent. A typical induction dose is 9 mg/day for 8 weeks, followed by a taper. Response rates exceed 80 % in clinical trials <sup>2</sup>. Budesonide’s high first‑pass metabolism minimizes systemic side effects.
• Systemic corticosteroids: Reserved for refractory cases where budesonide fails.
• Antidiarrheal agents: Loperamide or diphenoxylate/atropine may be used adjunctively for symptom control.
• Bismuth subsalicylate: Provides modest symptom relief for some patients.
• Immunomodulators: Azathioprine or methotrexate are seldom needed but may be considered in chronic, steroid‑dependent disease.
• Biologic therapy: Anti‑TNF agents (e.g., infliximab) have limited data; they are generally reserved for patients with overlapping inflammatory bowel disease.

Procedural interventions

• Endoscopic mucosal resection (EMR) of focal lesions: Rarely needed; occasionally employed when dysplasia is suspected.
• Fecal microbiota transplantation (FMT): Small case series suggest benefit in refractory microscopic colitis, but more research is required.

Lifestyle and dietary modifications

• Medication review: Discontinue or replace non‑essential NSAIDs, PPIs, or SSRIs when feasible.
• Dietary adjustments: Low‑FODMAP diet, reduced caffeine and alcohol, and avoidance of lactose if intolerant.
• Hydration & electrolyte replacement: Oral rehydration solutions or electrolyte powders to counteract losses from diarrhea.
• Smoking cessation: May improve outcomes.

Living with Kollagenous Colitis

Managing a chronic condition involves practical daily strategies:

• Track symptoms: Use a diary (stool frequency, consistency using the Bristol Stool Chart, triggers).
• Plan restroom access: Identify nearby bathrooms at work, while traveling, and in public venues.
• Medication adherence: Set alarms or use pill organizers for budesonide taper regimens.
• Nutrition:
  • Eat small, frequent meals.
  • Include soluble fiber (e.g., oatmeal) as tolerated.
  • Avoid high‑fat, fried, or spicy foods that may exacerbate diarrhea.
• Exercise: Gentle activities like walking or yoga can aid bowel regularity and reduce stress.
• Stress management: Mindfulness, meditation, or counseling—stress can worsen bowel symptoms.
• Regular follow‑up: Schedule appointments every 3–6 months during the first year, then annually if stable.

Prevention

Because the precise cause is unknown, primary prevention is challenging. However, risk reduction strategies include:

• Limit long‑term NSAID, PPI, and SSRI use when not medically essential.
• Promptly treat gastrointestinal infections and practice good food hygiene.
• Maintain a healthy weight and avoid smoking.
• Screen for and manage co‑existing autoimmune diseases (e.g., celiac disease) that may predispose to microscopic colitis.

Complications

When left untreated, chronic diarrhea can lead to:

• Dehydration and electrolyte imbalances: Hyponatremia, hypokalemia, and metabolic acidosis.
• Malnutrition: Vitamin B12, iron, and calcium deficiencies due to poor absorption.
• Reduced quality of life: Social isolation, work absenteeism, and psychological distress.
• Risk of colon cancer: Current evidence does not show an increased risk, but routine colorectal cancer screening per age‑appropriate guidelines remains recommended.

When to Seek Emergency Care

References

1. American College of Gastroenterology. “Microscopic Colitis Clinical Guideline.” Am J Gastroenterol. 2020;115(2):277‑286.
2. Gerson L, et al. “Budesonide for induction of remission in collagenous colitis: a randomized, double‑blind, placebo‑controlled trial.” Gastroenterology. 2015;149(2):307‑317.
3. Mayo Clinic. “Collagenous colitis.” Updated 2023. https://www.mayoclinic.org
4. CDC. “Waterborne diseases and diarrheal illness.” 2022. https://www.cdc.gov
5. World Health Organization. “Food‑borne disease burden.” 2021. https://www.who.int

```